More Hope, And More Demands, For Pancreatic Cancer Pipeline
Executive Summary
ASCO reflected diverse lay of the land for the challenging development space, with new drugs coming from Merrimack, Halozyme, Threshold and a range of immunotherapy combinations. Meanwhile, Celgene’s Abraxane appears to be on blockbuster track.